<DOC>
	<DOCNO>NCT00709059</DOCNO>
	<brief_summary>The objective study evaluate effectiveness PegIntron plus Rebetol combination treat patient chronic hepatitis C primary care set . Patients receive antiviral therapy prior current study . Only patient infect Hepatitis C Virus ( HCV ) genotype 1 , 4 , 5 , 6 enrol study . The study also explore influence liver fibrosis stage chance achieve sustain virologic response .</brief_summary>
	<brief_title>Efficacy PegIntron Rebetol Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 ( Study P04243 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Previously untreated ( 'treatment na√Øve ' ) adult ( 18 year ) treat physician decide start treatment PegIntron Rebetol Detectable Hepatitis C Virus Ribonucleic Acid ( HCVRNA ) serum Polymerase Chain Reaction ( PCR ) Repeated ( least 1 month interval ) serum transaminase ( alanine aminotransferase [ ALT ] ) level upper normal limit gender Documented chronic hepatitis C ( CHC ) genotype 1/4/5/6 A representative liver biopsy within 1 year prior inclusion , allow fibrosis grade METAVIR score F0 , F1 , F2 , F3 F4 Known hypersensitivity active ingredient constituent Pregnancy lactation Medically document history severe psychiatric disturbance , include severe depression , suicidal ideation suicide attempt Medically document history severe heart disease , include unstable uncontrolled cardiac disease , within last 6 month Severely weaken medical condition , include chronic renal insufficiency creatinine clearance &lt; 50 mL/minute Hepatitis immunologic origin medically document history autoimmune disease Severe hepatic disorder decompensated cirrhosis Preexisting thyroid disorder , except control classical treatment Epilepsy central nervous system disorder Hemoglobin pathology , eg , thalassaemia , sickle cell anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>hepatitis C</keyword>
</DOC>